Kaken Pharmaceuticals To License Its Antifungal Compound KP-103 To Dow Pharmaceutical Sciences

May 11, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Tokyo, May 11, 2006 (JCN) - Kaken Pharmaceutical announced on May 10 that it has concluded a licensing agreement with Dow Pharmaceutical Sciences for KP-103, Kaken Pharmaceutical's proprietary antifungal compound.

Twitter
LinkedIn
Facebook
Email
Print

Alliances Asia